Incyte Corp. (INCY) Reports Q4 2025 Revenue Growth of 28% to $1.51B Driven by Jakafi and Opzelura Sales
Incyte Corporation (NASDAQ:INCY) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 10, Incyte Corporation reported that the company’s Q4 2025 revenue climbed 28% to $1.51 billion, while full-year sales reached $5.14 billion. The company’s growth was largely propelled by its flagship product, Jakafi, which achieved annual sales of $3.093 billion, and the rapid expansion of Opzelura in the atopic dermatitis and vitiligo markets.
The company’s core business, excluding Jakafi, grew by 53% year-over-year in the final quarter. Key contributors included the hematology and oncology franchise, featuring Niktimvo and Monjuvi, which saw a 121% quarterly revenue surge. Incyte’s R&D efforts also reached a new level of maturity in 2025, with timely regulatory submissions for Jakafi XR and povercinib. Management expects this momentum to continue into 2026, forecasting core business growth of over 30% as the company moves towards a goal of 14 pivotal clinical trials by year-end.
Incyte Corporation (NASDAQ:INCY) now aims to nearly double its business size through a combination of internal innovation and strategic business development. While the company anticipates a mid-single-digit sales increase for Jakafi in 2026, it is heavily investing in next-gen treatments, such as its KRAS program and frontline DLBCL therapies.
Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in the US, Europe, Canada, and Japan. The company has collaboration and license agreements with Novartis, Lilly, and Syndax.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. Stock IPO Analysis | Ningtai Mold (NTMJ.US): From a Small Factory in Jiangyan to Nasdaq, the American Challenge for a Thirty-Year Mold Manufacturer
Ningtai Mould's performance is not optimistic.
Zoom (ZM.US) gets a bullish rating from Citi ahead of earnings: AI monetization signals emerge, target price raised to $131
Citibank has issued a forecast ahead of Zoom's Q3 financial report: Two major signals from channel partner surveys and Analyst Day both reinforce its view of a "moderate acceleration in the second half of the year."

JPMorgan: The CUDA moat is crumbling, and Nvidia faces real challenges beyond the CEO's departure
JPMorgan points out that Nvidia’s share in the 2026 compute protocol will drop to just 28%, with strong competition emerging from AMD, Google TPU, and others. Meanwhile, CUDA’s moat was breached by AI in only three days. The open-source market is facing tightened regulation and increased risks of export compliance. Although Nvidia’s current valuation remains attractive, both major drivers supporting high growth expectations have been undermined.
